Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Kineta, Inc.
A review of biopharma start-up dealmaking and financing activity from October through December 2018, based on data from Strategic Transactions.
As it moves away from virology, Gilead’s signs fibrosis collaboration with Scholar Rock. Novartis seeks to acquire CMDO that manufactures Kymriah, while Intrexon regains control of CAR-T program partnered with Merck KGAA. More deals from over the holiday period…
Genentech’s infectious diseases and immunology dealmaker speaks to Scrip about the significance of following the science when it comes to partnering.
Janssen and Bristol team to develop next-generation oral anticoagulant, while UCB buys Proximagen's nasal spray candidate and Duke spinout focused on genomics.
- Large Molecule
Drug Discovery Tools
- Natural Products
- Other Names / Subsidiaries
- Kineta Immuno-oncology, LLC
- Kineta RLB
- KPI Therapeutics, Inc.
- Kineta Chronic Pain, LLC